Company Performance Metrics
Carey Chern: Co-founder & CBO- Andrew Chang: Co-founder and CEO
DeepSeq.AI is revolutionizing AI-driven drug discovery by combining novel high-throughput wet lab assays with explainable generative AI to design biologics optimized for multiple key functions. Our proprietary platform generates massive-scale protein function data and models protein "grammar," enabling the design of therapeutics optimized
for conditional binding, manufacturability, efficacy, and more. Validated by paying customers, including several top global biopharma companies, and protected by a granted patent, DeepSeq.AI's technology is setting new standards in biologics discovery. Our approach has been further endorsed by investments from leading biotech accelerators, such as Merck DSS and UC Berkeley SkyDeck, as well as a prestigious NSF and DARPA grant. Together, we are accelerating the future of biologics development.
